Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Parkinson's Disease~* Modified Hoehn \& Yahr Stage \< III~* Diagnosis of Parkinson's Disease made within past 3 years•~* Ability to complete questionnaires~* Willingness to go off parkinsonian medication for 12 hours prior to baseline and 56-week assessments~Exclusion Criteria:~* Other major diseases of the central nervous system~* History of stroke~* Use of antipsychotic neuroleptic medication within the last 6 months~* Symptomatic (secondary) parkinsonism~* Atypical parkinsonian variants~* Unstable medical or psychiatric illness~* Known kidney disease~* History of stereotactic brain surgery~* Significant cognitive impairment~* Inability to safely tolerate 8 ounces of water twice daily associated with the study medication~* Unable to avoid regular use of medications containing magnesium~* Treatment with another investigational drug within the last 30 days that may interfere with the study medication~* Pregnancy or nursing

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Hydrogen tablets (Type: EXPERIMENTAL): The ingredient in the tablet producing H2 is magnesium. Each tablet contains 80 mg magnesium, a safe level well below the recommended daily dietary allowance of 420 mg for men/ 320 mg for women. Dissolving one tablet in 250 mL of water will achieve a saturating H2 concentration of approximately 1.6 ppm. Twice a day subjects will dissolve a tablet into water and drink the effervescent water.
- Placebo tablets (Type: PLACEBO_COMPARATOR): effervescent placebo tablets will also contain 80 mg magnesium but do not generate hydrogen-enriched water

Based on this trial design, predict the completion outcome and termination type (if applicable).